banner
Products
Coordinated with a renowned corporation
Pharmaceutical API Raw Material CAS71125-38-7 Meloxicam

Pharmaceutical API Raw Material CAS71125-38-7 Meloxicam

Pharmaceutical API Raw Material CAS71125-38-7 Meloxicam Meloxicam, a non-steroidal anti-inflammatory agent, has been rep;
Basic Info
Model NO. Meloxicam 71125-38-7
CAS No 71125-38-7
Mf C14h13n3o4s2
Appearance White Powder
Grade Standard Medicine Grade
Shelf Life 2 Years
Transport Package Bag, Carton, Drum
Specification 25kg/drum
Trademark Arshine
Origin China
HS Code 2941101900
Production Capacity 200 Tons/Year
Product Description
Pharmaceutical API Raw Material CAS71125-38-7 Meloxicam Meloxicam, a non-steroidal anti-inflammatory agent, has been reported to inhibit the inducible isoform of Cox-2. Meloxicam is an inhibitor selective for Cox-2 (IC50 of 4.7 μM) over Cox-1 (IC50 of 36.6 μM). Studies suggest that Meloxicam is Cox-2 preferential,therefore it will probably not display a lower gastrointestinal toxicity than non-selective anti-inflammatory agents. This compound has been shown to also inhibit prostanoid synthesis in inflammatory cells. Additionally, Meloxicam has demonstrated the ability to non-competitively inhibit erythrocyte PGD (6-phosphogluconate dehydrogenase) activity in vitro. Meloxicam, a non-steroidal anti-inflammatory agent, has been reported to inhibit the inducible isoform of Cox-2. Meloxicam is an inhibitor selective for Cox-2 (IC50 of 4.7 μM) over Cox-1 (IC50 of 36.6 μM). Studies suggest that Meloxicam is Cox-2 preferential,therefore it will probably not display a lower gastrointestinal toxicity than non-selective anti-inflammatory agents. This compound has been shown to also inhibit prostanoid synthesis in inflammatory cells. Additionally, Meloxicam has demonstrated the ability to non-competitively inhibit erythrocyte PGD (6-phosphogluconate dehydrogenase) activity in vitro.
Meloxicam is a non-steroidal antipyretic and analgesic anti-inflammatory drug, not a hormonal drug. It has strong anti-inflammatory, analgesic and antipyretic effects, and can selectively inhibit cyclooxygenase-2 (COX-2). Activity, thereby blocking prostaglandin synthesis, inhibiting prostaglandin biosynthesis at the Chemicalbook site of the inflammatory department is stronger than prostaglandin biosynthesis in the gastric mucosa or kidney, and is more safe than other NSAIDs. It is mainly used to relieve the symptoms of osteoarthritis, painful osteoarthritis, rheumatoid arthritis and joint spondylitis.For rheumatoid arthritis, rheumatoid arthritis, osteoarthritis, soft tissue injury and pain. The overview, pharmacological effects, pharmacokinetics, synthesis, and use of meloxicam were edited by Shi Yan of Chemicalbook. (2015-11-23 Chemicalbook)Adverse reactionsIndigestion, abdominal pain, nausea, diarrhea, elevated liver enzymes, dizziness, headache, rash, and anemia can occur. Occasionally edema, elevated blood pressure, mild serum creatinine or urea nitrogen abnormality, acute renal failure, gastric ulcer, gastric bleeding, gastric perforation, leukocytes, and thrombocytopenia.
PRODUCT NAME
TEST ITEMS SPECIFICATIONRESULTS
DescriptionWhite Or Almost White Crystalline PowderWhite Powder
IdentificationInfrared AbsorptionPositive
Assay97.0~103.0%99.2%
Melting Point33~37ºC34.5~36.5ºC
Loss On Drying0.5%max0.30%
Organic Volatile Impurities2500PPm max<1000PPm
Residual SolventsMeet the requirements.(USP29)Confirms
Chromatographic puritysum of impurities:3.0%max<3.0%
ConclusionThe specification conform with USP32 standard

Pharmaceutical API Raw Material CAS71125-38-7 Meloxicam

Pharmaceutical API Raw Material CAS71125-38-7 Meloxicam

Pharmaceutical API Raw Material CAS71125-38-7 Meloxicam

Pharmaceutical API Raw Material CAS71125-38-7 Meloxicam

Pharmaceutical API Raw Material CAS71125-38-7 Meloxicam

Send inquiry